<DOC>
	<DOCNO>NCT02711969</DOCNO>
	<brief_summary>An open study evaluate safety apatinib mesylate ( YN968D1 ) 1,000mg monotherapy patient unresectable locally advanced metastatic Gastric cancer fail standard therapy .</brief_summary>
	<brief_title>A Study Apatinib Mesylate ( YN968D1 ) 1,000mg Gastric Cancer Patient Failed Standard Treatment</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>19 year age old Subjects histologically confirm unresectable locally advanced metastatic adenocarcinoma stomach gastroesophageal junction Failure noncompliance exist standard treatment without alternative treatment Measurable disease measure proper image examination define RECIST 1.1 Life expectancy ≥ 3 month Subject must suitable oral administration study medication Subject submit write consent form participate test Adequate bone marrow , renal , liver function Electrocorticography ( ECOG ) performance status ≤ 2 Ability willingness comply study protocol duration study Pregnant lactate woman Therapy clinically significant systemic anticoagulant antithrombotic agent within 7 day prior first schedule dose YN968D1 Hemoptysis within 3 month prior first schedule dose YN968D1 Cytotoxic chemotherapy , immunotherapy , radiotherapy target therapy within 4 week ( 6 week case mitomycin C , nitrosourea , lomustine ) prior first schedule dose YN968D1 Surgery biopsy within 28 day prior first schedule dose YN968D1 Minor surgery within 7 day prior first schedule dose YN968D1 Patients experience use YN968D1 Concomitant treatment strong inhibitor inducer CYP3A4 , CYP2C9 CYP2C19 Known history human immunodeficiency virus infection ( HIV ) Medical history cancer ( include blood cancer ) 5 year Radiology therapy target lesion within 28 day , diagnosis cancer within 14 day prior first schedule dose YN968D1 History bleed diathesis bleeding within 14 day prior enrollment Medical history clinically significant thrombosis ( bleed clot disorder ) within past 3months History nonmalignant GI bleeding , gastric stress ulceration , peptic ulcer disease within past 3months History idiopathic hereditary angioedema , sickle cell hemolytic anemia History uncontrolled hypertension opinion investigator Complete Left bundle branch block ( LBBB ) bifascicular ( RBBB leave anterior posterior hemiblock ) Clinically significant ST segment T wave abnormality Abnormal atrial fibrillation History ECOG leave ventricular ejection fraction ( LVEF ) abnormality last 3 month opinion investigator Myocardial infarction unstable angina pectoris within 6 month prior start study medication Congestive heart failure ( New York Heart Association class IIIIV ) History significant cardiovascular disease vascular disease within last 6 month History clinically significant glomerulonephritis , biopsy proven tubulointerstitial nephritis , crystal nephropathy , renal insufficiency Treatment investigational agent within long time frame either 5 halflives 30 day initiate study drug Halflife investigator drug pass fivefold 30 day prior clinical trial Known recreational substance use psychiatric illness , opinion Investigator , may affect compliance schedule visit Known hypersensitivity YN968D1 component formulation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>